Another of the psychiatry drugs Neurocrine Biosciences licensed from Takeda has stumbled in the clinic. | Another of the ...

Lumateperone is approved as an adjunctive treatment for MDD, expanding its indications beyond schizophrenia and bipolar ...

The aim was to measure depression severity change from baseline to day five using the Montgomery-Åsberg Depression Rating Scale.

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Phase 2 study evaluating the efficacy, safety and tolerability of investigational compound NBI-1070770 in adults with major ...

To provide some solid data, the authors of the new study gave LSD to a group of patients in New Zealand, and instructed them ...

The J&J antipsychotic drug Caplyta won FDA approval for depression, a broader indication that could help the medicine become ...

Creatine supplementation may modestly reduce depressive symptoms, but the effect is small, uncertain, and likely influenced ...

A neuroscientist, he employed a battery of high-tech tools in devising a fast-acting therapy that targets the area of the ...

Imagine wading through severe depression for years, taking medication after medication, with no relief. Now, envision discovering that what you were facing was not major depression but bipolar ...

Scientists have developed a portable biosensor that can detect levels of BDNF, a protein linked to mental health conditions ...

The FDA approved lumateperone (Caplyta) as an adjunctive therapy with antidepressants for the treatment of major depressive ...

As the days shorten, the clocks roll back and the holiday season approaches, millions of Americans brace for seasonal ...